小児成長ホルモン欠乏症の世界市場レポート 2025年

小児成長ホルモン欠乏症市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR9.1％で58億8,000万米ドルに成長します。予測期間中の成長は、ヘルスケアインフラとケアへのアクセスの拡大、成長ホルモン療法の進歩、認知度の向上と患者の支持、政府の支援政策とヘルスケアイニシアチブ、PGHDの有病率の上昇に起因しています。予測期間における主な動向としては、新規治療法の開発、個別化治療アプローチ、製品の革新、遠隔医療や遠隔モニタリング、個別化医療や遺伝子検査の進歩などが挙げられます。

小児疾患の有病率の上昇は、小児成長ホルモン欠乏症市場の成長を促進すると予測されます。小児疾患には、主に乳幼児期から思春期までの小児が罹患する病状や病気が含まれます。これらの疾患の発生が増加している背景には、環境要因、検出方法の進歩、ライフスタイルの変化、遺伝的素因、小児の慢性疾患やアレルギーの発生率の増加があります。このような疾患は、成長ホルモンの分泌を司る視床下部や下垂体に影響を与えることで、小児成長ホルモン欠乏症（GHD）の一因となる可能性があります。例えば、米国を拠点とする政府機関である国連児童基金（ユニセフ）によると、2022年には約490万人の5歳未満児が命を落とし、1日平均1万3,400人が亡くなっています。5歳未満児死亡の世界の主要原因には、肺炎、下痢、マラリアなどの感染症に加え、早産や分娩中の合併症も含まれます。その結果、小児疾患の有病率の増加が小児成長ホルモン欠乏症市場の拡大に拍車をかけています。

この市場で事業を展開する企業は、患者のコンプライアンスと利便性を高めるため、長時間作用型週1回投与型ヒト成長ホルモンアナログ製剤を含む革新的な治療法の開発を優先しています。週1回投与の長時間作用型ヒト成長ホルモン（HGH）アナログは、天然のヒト成長ホルモンを改良したもので、体内での作用時間が長くなるように設計されています。例えば、2023年6月、米国の製薬会社ファイザー社と米国の医薬品会社OPKOヘルス社は共同で、NGENLA（somatrogon-ghla）が米国の政府機関である食品医薬品局（FDA）から承認されたことを発表しました。この週1回投与のヒト成長ホルモンアナログ製剤は、内因性成長ホルモンの分泌不全により成長不全に陥った3歳以上の小児患者を対象としています。本治療は、従来の治療法では通常毎日投与が必要であった注射の頻度を減らすことにより、患者のアドヒアランスを向上させることを目的としています。臨床試験では、NGENLAが毎日の成長ホルモン治療に匹敵する有効性を提供し、小児とその家族にとってより便利で管理しやすい解決策を提供することが実証されています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界小児成長ホルモン欠乏症PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の小児成長ホルモン欠乏症市場：成長率分析
• 世界の小児成長ホルモン欠乏症市場の実績：規模と成長, 2019-2024
• 世界の小児成長ホルモン欠乏症市場の予測：規模と成長, 2024-2029, 2034F
• 世界小児成長ホルモン欠乏症総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の小児成長ホルモン欠乏症市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 先天性成長ホルモン欠乏症
• 後天性GH欠乏症
• 特発性成長ホルモン欠乏症
• 世界の小児成長ホルモン欠乏症市場：製品別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 組み換えヒト成長ホルモン（rhGH）
• ヒト成長ホルモン（HGH）類似体
• 長時間作用型成長ホルモン
• 世界の小児成長ホルモン欠乏症市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 皮下
• 筋肉内
• オーラル
• 世界の小児成長ホルモン欠乏症市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界の小児成長ホルモン欠乏症市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 成長ホルモン欠乏症
• 特発性低身長
• ターナー症候群
• 妊娠週数に対して小さい
• プラダー・ウィリー症候群
• その他の用途
• 世界の小児成長ホルモン欠乏症市場先天性成長ホルモン欠乏症の分類（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 単独成長ホルモン欠乏症
• 下垂体ホルモン複合欠乏症
• 世界の小児成長ホルモン欠乏症市場、後天性成長ホルモン欠乏症のタイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 下垂体腫瘍による成長ホルモン欠乏症
• 脳損傷による成長ホルモン欠乏症
• 放射線療法によるGH欠乏症
• 世界の小児成長ホルモン欠乏症市場特発性成長ホルモン欠乏症の病型別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 原発性特発性成長ホルモン欠乏症
• 二次性特発性成長ホルモン欠乏症

第7章 地域別・国別分析

• 世界の小児成長ホルモン欠乏症市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の小児成長ホルモン欠乏症市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 小児成長ホルモン欠乏症市場：競合情勢
• 小児成長ホルモン欠乏症市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • Novo Nordisk A/S Overview, Products and Services, Strategy and Financial Analysis
  • Genentech Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Merck KGaA Darmstadt Germany Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Teva Pharmaceutical Industries Ltd.
• Mylan N.V.
• Sandoz International GmbH
• Sun Pharmaceutical Industries Ltd.
• I-Mab Biopharma Co. Ltd.
• Ipsen Pharma
• Gedeon Richter Plc
• Ferring Pharmaceuticals
• Celltrion Healthcare Co. Ltd.
• OPKO Health Inc.
• Zhejiang Hisun Pharmaceutical Co., Ltd.
• Dong-A ST Co. Ltd.
• Ascendis Pharma A/S
• AnkeBio
• Versartis Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 小児成長ホルモン欠乏症市場2029：新たな機会を提供する国
• 小児成長ホルモン欠乏症市場2029：新たな機会を提供するセグメント
• 小児成長ホルモン欠乏症市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Pediatric growth hormone deficiency (PGHD) is a condition where the pituitary gland fails to produce adequate growth hormone, resulting in slow growth, short stature, and delayed puberty. This condition can be either congenital or acquired, with treatment usually involving recombinant human growth hormone (rhGH) therapy to help ensure normal growth and development.

The primary types of pediatric growth hormone deficiency are congenital GH deficiency, acquired GH deficiency, and idiopathic GH deficiency. Congenital growth hormone deficiency (GHD) is a rare condition present from birth, where the body cannot produce enough growth hormone. Various treatments are available, including recombinant human growth hormone (rhGH), human growth hormone (hGH) analogs, and long-acting growth hormones, which can be administered via subcutaneous, intramuscular, or oral routes. These treatments are distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and are used to address conditions such as growth hormone deficiency, idiopathic short stature, Turner syndrome, small for gestational age, Prader-Willi syndrome, and more.

The pediatric growth hormone deficiency market research report is one of a series of new reports from The Business Research Company that provides pediatric growth hormone deficiency market statistics, including pediatric growth hormone deficiency industry global market size, regional shares, competitors with a pediatric growth hormone deficiency market share, detailed pediatric growth hormone deficiency market segments, market trends and opportunities, and any further data you may need to thrive in the pediatric growth hormone deficiency industry. This pediatric growth hormone deficiency market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The pediatric growth hormone deficiency market size has grown strongly in recent years. It will grow from $3.80 billion in 2024 to $4.16 billion in 2025 at a compound annual growth rate (CAGR) of 9.4%. The growth during the historic period can be credited to greater awareness of pediatric growth disorder treatments, enhanced diagnostic capabilities, increased investments in research and development of next-generation products, and the expansion of public insurance schemes.

The pediatric growth hormone deficiency market size is expected to see strong growth in the next few years. It will grow to $5.88 billion in 2029 at a compound annual growth rate (CAGR) of 9.1%. The growth during the forecast period can be attributed to the expansion of healthcare infrastructure and access to care, advancements in growth hormone therapies, increased awareness and patient advocacy, supportive government policies and healthcare initiatives, and the rising prevalence of PGHD. Key trends in the forecast period include the development of novel therapies, personalized treatment approaches, product innovation, telemedicine and remote monitoring, as well as advancements in personalized medicine and genetic testing.

The rising prevalence of pediatric diseases is anticipated to drive the growth of the pediatric growth hormone deficiency market. Pediatric diseases encompass medical conditions or illnesses that primarily affect children from infancy to adolescence. The increasing occurrence of these diseases can be attributed to environmental factors, advancements in detection methods, lifestyle changes, genetic predispositions, and a growing incidence of chronic conditions and allergies among children. Such diseases can contribute to pediatric growth hormone deficiency (GHD) by impacting the hypothalamus or pituitary gland, which are responsible for growth hormone production. For example, according to the United Nations Children's Fund (UNICEF), a US-based government organization, approximately 4.9 million children under the age of five lost their lives in 2022, averaging 13,400 deaths per day. Leading global causes of under-five mortality included infectious diseases such as pneumonia, diarrhea, and malaria, along with complications from preterm birth and intrapartum-related issues. As a result, the increasing prevalence of pediatric diseases is fueling the expansion of the pediatric growth hormone deficiency market.

Companies operating in this market are prioritizing the development of innovative treatments, including long-acting, once-weekly human growth hormone analogs, to enhance patient compliance and convenience. A long-acting, once-weekly human growth hormone (HGH) analog is a modified version of natural human growth hormone, designed to have a prolonged duration of action in the body. For instance, in June 2023, Pfizer Inc., a US-based pharmaceutical company, and OPKO Health Inc., a US-based medication company, jointly announced the approval of NGENLA (somatrogon-ghla) by the Food and Drug Administration (FDA), a US-based government agency. This once-weekly human growth hormone analog is intended for pediatric patients aged three years and older who experience growth failure due to inadequate secretion of endogenous growth hormone. The treatment aims to improve patient adherence by reducing the frequency of injections, as traditional therapies typically require daily dosing. Clinical trials have demonstrated that NGENLA provides efficacy comparable to daily growth hormone treatments, offering a more convenient and manageable solution for children and their families.

In December 2024, Double Point Ventures, a US-based venture capital fund, acquired Lumos Pharma for $38 million. This acquisition is intended to accelerate the development of Lumos' lead therapeutic candidate, LUM-201, while expanding its portfolio of treatments for rare diseases. Lumos Pharma, a US-based biopharmaceutical company, specializes in developing therapies for rare diseases, particularly those associated with growth hormone deficiencies.

Major players in the pediatric growth hormone deficiency market are Pfizer Inc., Eli Lilly and Company, Novo Nordisk A/S, Genentech Inc., Merck KGaA Darmstadt Germany, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sandoz International GmbH, Sun Pharmaceutical Industries Ltd., I-Mab Biopharma Co. Ltd., Ipsen Pharma, Gedeon Richter Plc, Ferring Pharmaceuticals, Celltrion Healthcare Co. Ltd., OPKO Health Inc., Zhejiang Hisun Pharmaceutical Co., Ltd., Dong-A ST Co. Ltd., Ascendis Pharma A/S, AnkeBio, Versartis Inc., Changchun Changsheng Life Sciences Ltd.

North America was the largest region in the pediatric growth hormone deficiency market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pediatric growth hormone deficiency report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the pediatric growth hormone deficiency market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The pediatric growth hormone deficiency market consists of sales of synthetic growth hormone, growth hormone releasing hormone, and long-acting growth hormone therapies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Pediatric Growth Hormone Deficiency Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pediatric growth hormone deficiency market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for pediatric growth hormone deficiency ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The pediatric growth hormone deficiency market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Congenital GH Deficiency; Acquired GH Deficiency; Idiopathic GH deficiency
• 2) By Product: Recombinant Human Growth Hormone (rhGH); Human Growth Hormone (HGH) Analogs; Long-Acting Growth Hormones
• 3) By Route Of Administration: Subcutaneous; Intramuscular; Oral
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 5) By Application: Growth Hormone Deficiency; Idiopathic Short Stature; Turner Syndrome; Small For Gestational Age; Prader Willi Syndrome; Other Applications
• Subsegments:
• 1) By Congenital GH Deficiency: Isolated GH Deficiency; Combined Pituitary Hormone Deficiency
• 2) By Acquired GH Deficiency: GH Deficiency Due To Pituitary Tumors; GH Deficiency Due To Brain Injury; GH Deficiency Due To Radiation Therapy
• 3) By Idiopathic GH Deficiency: Primary Idiopathic GH Deficiency; Secondary Idiopathic GH Deficiency
• Companies Mentioned:Pfizer Inc.; Eli Lilly and Company; Novo Nordisk A/S; Genentech Inc.; Merck KGaA Darmstadt Germany
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Pediatric Growth Hormone Deficiency Market Characteristics

3. Pediatric Growth Hormone Deficiency Market Trends And Strategies

4. Pediatric Growth Hormone Deficiency Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Pediatric Growth Hormone Deficiency Growth Analysis And Strategic Analysis Framework

• 5.1. Global Pediatric Growth Hormone Deficiency PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Pediatric Growth Hormone Deficiency Market Growth Rate Analysis
• 5.4. Global Pediatric Growth Hormone Deficiency Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Pediatric Growth Hormone Deficiency Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Pediatric Growth Hormone Deficiency Total Addressable Market (TAM)

6. Pediatric Growth Hormone Deficiency Market Segmentation

• 6.1. Global Pediatric Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Congenital GH Defficiency
• Acquired GH dificiency
• Idiopathic GH deficiency
• 6.2. Global Pediatric Growth Hormone Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Recombinant Human Growth Hormone (rhGH)
• Human Growth Hormone (HGH) Analogs
• Long-Acting Growth Hormones
• 6.3. Global Pediatric Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Subcutaneous
• Intramuscular
• Oral
• 6.4. Global Pediatric Growth Hormone Deficiency Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.5. Global Pediatric Growth Hormone Deficiency Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Growth Hormone Deficiency
• Idiopathic Short Stature
• Turner Syndrome
• Small For Gestational Age
• Prader Willi Syndrome
• Other Applications
• 6.6. Global Pediatric Growth Hormone Deficiency Market, Sub-Segmentation Of Congenital GH Deficiency, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Isolated GH Deficiency
• Combined Pituitary Hormone Deficiency
• 6.7. Global Pediatric Growth Hormone Deficiency Market, Sub-Segmentation Of Acquired GH Deficiency, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• GH Deficiency Due To Pituitary Tumors
• GH Deficiency Due To Brain Injury
• GH Deficiency Due To Radiation Therapy
• 6.8. Global Pediatric Growth Hormone Deficiency Market, Sub-Segmentation Of Idiopathic GH Deficiency, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Primary Idiopathic GH Deficiency
• Secondary Idiopathic GH Deficiency

7. Pediatric Growth Hormone Deficiency Market Regional And Country Analysis

• 7.1. Global Pediatric Growth Hormone Deficiency Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Pediatric Growth Hormone Deficiency Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Pediatric Growth Hormone Deficiency Market

• 8.1. Asia-Pacific Pediatric Growth Hormone Deficiency Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Pediatric Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Pediatric Growth Hormone Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Pediatric Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Pediatric Growth Hormone Deficiency Market

• 9.1. China Pediatric Growth Hormone Deficiency Market Overview
• 9.2. China Pediatric Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Pediatric Growth Hormone Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Pediatric Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Pediatric Growth Hormone Deficiency Market

• 10.1. India Pediatric Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Pediatric Growth Hormone Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Pediatric Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Pediatric Growth Hormone Deficiency Market

• 11.1. Japan Pediatric Growth Hormone Deficiency Market Overview
• 11.2. Japan Pediatric Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Pediatric Growth Hormone Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Pediatric Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Pediatric Growth Hormone Deficiency Market

• 12.1. Australia Pediatric Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Pediatric Growth Hormone Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Pediatric Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Pediatric Growth Hormone Deficiency Market

• 13.1. Indonesia Pediatric Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Pediatric Growth Hormone Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Pediatric Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Pediatric Growth Hormone Deficiency Market

• 14.1. South Korea Pediatric Growth Hormone Deficiency Market Overview
• 14.2. South Korea Pediatric Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Pediatric Growth Hormone Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Pediatric Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Pediatric Growth Hormone Deficiency Market

• 15.1. Western Europe Pediatric Growth Hormone Deficiency Market Overview
• 15.2. Western Europe Pediatric Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Pediatric Growth Hormone Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Pediatric Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Pediatric Growth Hormone Deficiency Market

• 16.1. UK Pediatric Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Pediatric Growth Hormone Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Pediatric Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Pediatric Growth Hormone Deficiency Market

• 17.1. Germany Pediatric Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Pediatric Growth Hormone Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Pediatric Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Pediatric Growth Hormone Deficiency Market

• 18.1. France Pediatric Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Pediatric Growth Hormone Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Pediatric Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Pediatric Growth Hormone Deficiency Market

• 19.1. Italy Pediatric Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Pediatric Growth Hormone Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Pediatric Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Pediatric Growth Hormone Deficiency Market

• 20.1. Spain Pediatric Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Pediatric Growth Hormone Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Pediatric Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Pediatric Growth Hormone Deficiency Market

• 21.1. Eastern Europe Pediatric Growth Hormone Deficiency Market Overview
• 21.2. Eastern Europe Pediatric Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Pediatric Growth Hormone Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Pediatric Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Pediatric Growth Hormone Deficiency Market

• 22.1. Russia Pediatric Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Pediatric Growth Hormone Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Pediatric Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Pediatric Growth Hormone Deficiency Market

• 23.1. North America Pediatric Growth Hormone Deficiency Market Overview
• 23.2. North America Pediatric Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Pediatric Growth Hormone Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Pediatric Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Pediatric Growth Hormone Deficiency Market

• 24.1. USA Pediatric Growth Hormone Deficiency Market Overview
• 24.2. USA Pediatric Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Pediatric Growth Hormone Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Pediatric Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Pediatric Growth Hormone Deficiency Market

• 25.1. Canada Pediatric Growth Hormone Deficiency Market Overview
• 25.2. Canada Pediatric Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Pediatric Growth Hormone Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Pediatric Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Pediatric Growth Hormone Deficiency Market

• 26.1. South America Pediatric Growth Hormone Deficiency Market Overview
• 26.2. South America Pediatric Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Pediatric Growth Hormone Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Pediatric Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Pediatric Growth Hormone Deficiency Market

• 27.1. Brazil Pediatric Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Pediatric Growth Hormone Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Pediatric Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Pediatric Growth Hormone Deficiency Market

• 28.1. Middle East Pediatric Growth Hormone Deficiency Market Overview
• 28.2. Middle East Pediatric Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Pediatric Growth Hormone Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Pediatric Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Pediatric Growth Hormone Deficiency Market

• 29.1. Africa Pediatric Growth Hormone Deficiency Market Overview
• 29.2. Africa Pediatric Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Pediatric Growth Hormone Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Pediatric Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Pediatric Growth Hormone Deficiency Market Competitive Landscape And Company Profiles

• 30.1. Pediatric Growth Hormone Deficiency Market Competitive Landscape
• 30.2. Pediatric Growth Hormone Deficiency Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Novo Nordisk A/S Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Genentech Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Merck KGaA Darmstadt Germany Overview, Products and Services, Strategy and Financial Analysis

31. Pediatric Growth Hormone Deficiency Market Other Major And Innovative Companies

• 31.1. Teva Pharmaceutical Industries Ltd.
• 31.2. Mylan N.V.
• 31.3. Sandoz International GmbH
• 31.4. Sun Pharmaceutical Industries Ltd.
• 31.5. I-Mab Biopharma Co. Ltd.
• 31.6. Ipsen Pharma
• 31.7. Gedeon Richter Plc
• 31.8. Ferring Pharmaceuticals
• 31.9. Celltrion Healthcare Co. Ltd.
• 31.10. OPKO Health Inc.
• 31.11. Zhejiang Hisun Pharmaceutical Co., Ltd.
• 31.12. Dong-A ST Co. Ltd.
• 31.13. Ascendis Pharma A/S
• 31.14. AnkeBio
• 31.15. Versartis Inc.

32. Global Pediatric Growth Hormone Deficiency Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Pediatric Growth Hormone Deficiency Market

34. Recent Developments In The Pediatric Growth Hormone Deficiency Market

35. Pediatric Growth Hormone Deficiency Market High Potential Countries, Segments and Strategies

• 35.1 Pediatric Growth Hormone Deficiency Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Pediatric Growth Hormone Deficiency Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Pediatric Growth Hormone Deficiency Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer